A wrist-based optical blood-pressure monitor has the potential to replace cuff monitoring systems for ambulatory blood pressure, suggests a study in the journal Blood Pressure Monitoring. A press release from Aktiia, the Swiss-based company manufacturing the device, states that the novel system uses the same sensors to measure heart rate as those used in wearable devices.
Data from the CLASP study
The CLASP study enrolled 62 patients with MR grade 3+ or 4+ (56% functional, 36% degenerative, and 8% with mixed aetiology). The patients had a mean age of 76.5 years and 51.6% were in New York Heart Association (NYHA) class III or IV.1
LimFlow SA today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the LimFlow percutaneous deep vein arterialisation system. Results were presented on the podium at the 2019 Vascular InterVentional Advances conference (VIVA; 4–7 November, Las Vegas, USA) by Daniel Clair, PROMISE II principal investigator and chair of the department of surgery at the University of South Carolina (USC) and Palmetto Health-USC Medical Group.
Edwards Lifesciences has received the CE mark for its Sapien 3 transcatheter aortic valve implantation (TAVI) device to be used to manage aortic stenosis in low-risk patients. Both Edwards and Medtronic (with its CoreValve range) have FDA approval for their devices to be used for low-risk patients in the USA but, with this new CE mark approval, Edwards is the first TAVI company to have this indication in Europe.
It was announced today that results of the TANGO low-dose cohort compared to controls are positive, both for primary and secondary endpoints. These latest findings were presented by Ehrin Armstrong at the 2019 Vascular Interventional Advances conference (VIVA) in Las Vegas, USA (4–7 November). According to Armstrong, perivascular temsirolimus is being developed as a “viable alternative” to prevent restenosis after below-the-knee (BTK) peripheral artery interventions, and TANGO high-dose data is “forthcoming”.
Medtronic today announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and the launch of the Valiant Navion thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). The news marks the third major geographical launch of the Valiant Navion, following US Food and Drug Administration (FDA) and CE mark approvals in late 2018.
The Solaris (Scitech Medical) is a flexible self-expanding endograft, comprised of a thin multi-direction durable electrospinning PTFE membrane encapsulating a Nitinol stent structure. The device has been engineered to effectively cover and instantaneously seal off diseased tissue with a higher multidirectional resistance force, providing an endoluminal bypass option for physicians faced with complex lesions.
There is a growing need for wound care amid higher rates of chronic wounds—somewhere in the vicinity of five to seven million in the United States per year—at a cost level in excess of US$25 billion, Venita Chandra (Stanford University School of Medicine, Stanford, California, USA) told the America College of Wound Healing and Tissue Repair (ACWHTR; 11–12 October 2019, Chicago, USA).
Clinical data presented at the 2019 European Cardio-Thoracic Surgery (EACTS) annual meeting (3-5 October, Lisbon, Portugal), from two prospective trials of the VEST external stent for vein grafts during coronary artery bypass surgery (CABG), showed low major adverse cardiac and cerebrovascular events (MACCE) rates up to three years, excellent patency rates and a significant reduction in the progression of vein graft disease.
Philips has received US Food and Drug Administration (FDA) approval for two Stellarex 0.035” low-dose (200mm and 150mm) drug-coated balloons for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries.
Michael R Jaff is to be vice president, clinical affairs, innovation and technology, peripheral interventions of Boston Scientific by January 2020. In this role, a press release reports, Jaff will lead clinical and medical affairs strategies to support the development and commercialisation of the company’s peripheral vascular medical device portfolio, and drive engagement with external stakeholders to advance technologies that deliver strong clinical value and enable patient care.
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389